Dengue, the break-bone fever, is a serious mosquito-borne disease that makes around 400 million people sick every year. Close to 5 lakh patients need to be hospitalized, out of which 22 thousand can’t survive. More than 100 developing countries in the tropical as well as subtropical regions in Latin America and Asia are affected by Dengue each year.
Dengvaxia is the first vaccine for Dengue, approved for use in endemic countries after more than two decades of hardcore research and testing on 29,000 patients. Mexico has allowed the use of Dengvaxia from Sanofi, France in age group 9-45 years in the most affected parts of the country. Dengue vaccine protects from all the four serotypes of Dengue viruses.
Sanofi is in talks with the Indian authorities for launching of Dengvaxia in India, as the successful clinical trials have already been conducted on Indian adults in Delhi, Ludhiana, Bengaluru, Pune and Kolkata.
However, Dengvaxia didn’t prove to be effective and safe to be used in children below 9 years. Also, Dengvaxia claims to decrease the risk of developing Dengue by only ~60% which is quite low for a vaccine. Still, Dengvaxia is definitely a major health innovation and an important step in preventing Dengue alongside, other preventive measures like vector control .